{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:26:07Z","timestamp":1720571167654},"reference-count":8,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,9]]},"DOI":"10.1182\/bloodadvances.2024013292","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T13:25:12Z","timestamp":1720531512000},"page":"3560-3561","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Understanding CAR-T therapy in myeloma: 1 cell at a time"],"prefix":"10.1182","volume":"8","author":[{"given":"Madhav V.","family":"Dhodapkar","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"13","key":"2024070915310273700_bib1","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","article-title":"CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy","volume":"8","author":"Ledergor","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"2024070915310273700_bib2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in bone marrow tumor\u00a0and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"9","key":"2024070915310273700_bib3","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2024070915310273700_bib4","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood-2023-182298","article-title":"Biomarker correlates of response to ciltacabtagene autoleucel in patients with relapsed or refractory multiple myeloma from CARTITUDE-1, a phase 1b\/2 open-label study, at the \u223c3 year follow-up","volume":"142","author":"Montes de Oca","year":"2023","journal-title":"Blood"},{"key":"2024070915310273700_bib5","article-title":"Immune status and selection of patients for immunotherapy in myeloma: a proposal","author":"Dhodapkar","year":"2  2024","journal-title":"Blood Adv"},{"issue":"12","key":"2024070915310273700_bib6","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat\u00a0Rev Drug Discov"},{"issue":"2","key":"2024070915310273700_bib7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1158\/2643-3230.BCD-23-0212","article-title":"Understanding mechanisms of response to CAR T-cell therapy through single-cell sequencing: insights and challenges","volume":"5","author":"Haradhvala","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"15","key":"2024070915310273700_bib8","doi-asserted-by":"crossref","first-page":"e167629","DOI":"10.1172\/JCI167629","article-title":"Regulation of antigen-specific T\u00a0cell infiltration and spatial architecture in multiple myeloma and premalignancy","volume":"133","author":"Robinson","year":"2023","journal-title":"J\u00a0Clin Invest"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3560\/2233940\/blooda_adv-2024-013292-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3560\/2233940\/blooda_adv-2024-013292-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T16:34:06Z","timestamp":1720542846000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/13\/3560\/516892\/Understanding-CAR-T-therapy-in-myeloma-1-cell-at-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":8,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013292","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]}}}